Focus Partners Wealth’s Altimmune ALT Stock Holding History

Focus Partners Wealth’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-122,539	Closed	-$884K	–	1905
2024 Q4	$884K	Buy	+122,539	New	+$936K	﹤0.01%	1095

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Focus Partners Wealth's ALT Position: Q1 2025 in Review

Focus Partners Wealth sold out of Altimmune (ALT) in Q1 2025, closing a stake of 122,539 shares — an estimated $884K sold.

Focus Partners Wealth first reported a position in ALT in Q4 2024 and held it in 1 quarter. The position peaked at $884K in Q4 2024. 176 funds tracked by Wall St. Rank hold ALT as of Q1 2025.

Focus Partners Wealth reported no remaining Altimmune position as of Q1 2025 after selling out during the quarter.
Focus Partners Wealth sold 122,539 Altimmune shares in Q1 2025, an estimated $884K.
Focus Partners Wealth first reported a position in Altimmune in Q4 2024 and held it in 1 quarter.
Focus Partners Wealth's Altimmune position peaked at $884K in Q4 2024.
176 funds tracked by Wall St. Rank held Altimmune as of Q1 2025.

Based on Focus Partners Wealth's 13F filing for Q1 2025, filed 15 May 2025.